{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:33:21Z","timestamp":1786980801176,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10557-022-07381-5","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T11:02:41Z","timestamp":1663585361000},"page":"109-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Direct Oral Anticoagulation Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves: a Retrospective, Real-World Cohort Study"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6005-5458","authenticated-orcid":false,"given":"Rachel","family":"Eikelboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Sibilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Belley-Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"issue":"1","key":"7381_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej J, B\u00f6rschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4\u201320.","journal-title":"Circ Res"},{"key":"7381_CR2","unstructured":"Heart & Stroke. Atrial fibrillation. Available from: http:\/\/www.heartandstroke.ca\/heart\/conditions\/atrial-fibrillation. Accessed\u00a016 March\u00a02022"},{"issue":"4","key":"7381_CR3","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/joa3.12588","volume":"37","author":"M Kozie\u0142","year":"2021","unstructured":"Kozie\u0142 M, Teutsch C, Bayer V, et al. Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world. J Arrhythm. 2021;37(4):990\u20131006.","journal-title":"J Arrhythm"},{"issue":"9921","key":"7381_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet"},{"key":"7381_CR5","doi-asserted-by":"crossref","unstructured":"Thomas KL, Jackson LR 2nd, Shrader P, et al. Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (outcomes registry for better informed treatment for atrial fibrillation). J Am Heart Assoc. 2017;6(12).","DOI":"10.1161\/JAHA.117.006475"},{"issue":"12","key":"7381_CR6","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/europace\/euz220","volume":"21","author":"A Banerjee","year":"2019","unstructured":"Banerjee A, Allan V, Denaxas S, et al. Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. Europace. 2019;21(12):1776\u201384.","journal-title":"Europace"},{"issue":"13","key":"7381_CR7","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206\u201314.","journal-title":"N Engl J Med"},{"key":"7381_CR8","doi-asserted-by":"publisher","first-page":"d124","DOI":"10.1136\/bmj.d124","volume":"342","author":"JB Olesen","year":"2011","unstructured":"Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.","journal-title":"BMJ"},{"issue":"5","key":"7381_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093\u2013100.","journal-title":"Chest"},{"issue":"4","key":"7381_CR10","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","volume":"77","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;77(4):e25\u2013197.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"7381_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561\u2013632.","journal-title":"Eur Heart J"},{"issue":"22","key":"7381_CR12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","volume":"383","author":"HP Guimar\u00e3es","year":"2020","unstructured":"Guimar\u00e3es HP, Lopes RD, de Barros E, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383(22):2117\u201326.","journal-title":"N Engl J Med"},{"issue":"20","key":"7381_CR13","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.jacc.2010.06.039","volume":"56","author":"J Afilalo","year":"2010","unstructured":"Afilalo J, Eisenberg MJ, Morin JF, et al. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. J Am Coll Cardiol. 2010;56(20):1668\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"7381_CR14","unstructured":"Shim CY, Seo J, Kim YJ, et al.\u00a0Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial.\u00a0J Thorac Cardiovasc Surg.\u00a02021."},{"key":"7381_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ahj.2018.07.006","volume":"205","author":"NM Van Mieghem","year":"2018","unstructured":"Van Mieghem NM, Unverdorben M, Valgimigli M, et al. Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation in atrial fibrillation-rationale and design of the ENVISAGE-TAVI AF trial. Am Heart J. 2018;205:63\u20139.","journal-title":"Am Heart J"},{"key":"7381_CR16","unstructured":"Collet JP, Van Belle E, Thiele H, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial.\u00a0Eur Heart J. 2022."},{"issue":"3","key":"7381_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1253\/circj.CJ-21-0564","volume":"86","author":"C Izumi","year":"2022","unstructured":"Izumi C, Miyake M, Fujita T, et al. Antithrombotic therapy for patients with atrial fibrillation and bioprosthetic valves- real-world data from the multicenter, prospective, observational BPV-AF registry. Circ J. 2022;86(3):440\u20138.","journal-title":"Circ J"},{"issue":"1","key":"7381_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jjcc.2020.02.006","volume":"76","author":"C Izumi","year":"2020","unstructured":"Izumi C, Miyake M, Amano M, et al. Registry of antithrombotic therapy in atrial fibrillation patients with bioprosthetic valves: a retrospective observational study. J Cardiol. 2020;76(1):44\u201350.","journal-title":"J Cardiol"},{"issue":"22","key":"7381_CR19","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"11","key":"7381_CR20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"7381_CR21","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.jcin.2020.09.013","volume":"13","author":"H Kawashima","year":"2020","unstructured":"Kawashima H, Watanabe Y, Hioki H, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR. JACC Cardiovasc Interv. 2020;13(22):2587\u201397.","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"7381_CR22","doi-asserted-by":"publisher","first-page":"e019588","DOI":"10.1161\/JAHA.120.019588","volume":"10","author":"MN Young","year":"2021","unstructured":"Young MN, Kearing S, Malenka D, Goodney PP, Skinner J, Iribarne A. Geographic and demographic variability in transcatheter aortic valve replacement dispersion in the United States. J Am Heart Assoc. 2021;10(12):e019588.","journal-title":"J Am Heart Assoc"},{"key":"7381_CR23","doi-asserted-by":"crossref","unstructured":"Ranasinghe MP, Peter K, McFadyen JD. Thromboembolic and bleeding complications in transcatheter aortic valve implantation: insights on mechanisms, prophylaxis and therapy. J Clin Med. 2019;8(2).","DOI":"10.3390\/jcm8020280"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07381-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-022-07381-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07381-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T05:32:07Z","timestamp":1708320727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-022-07381-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["7381"],"URL":"https:\/\/doi.org\/10.1007\/s10557-022-07381-5","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"assertion":[{"value":"3 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). Parts of this material are based on data and information compiled and provided by CIHI and by the Ontario MOH. The analyses, conclusions, opinions, and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred. The authors acknowledge that the clinical registry data used in this manuscript is from participating hospitals through CorHealth Ontario, which serves as an advisory body to the Ministry of Health (MOH), is funded by the MOH, and is dedicated to improving the quality, efficiency, access, and equity in the delivery of the continuum of adult cardiac, vascular, and stroke services in Ontario, Canada. We thank IQVIA Solutions Canada Inc. for use of their Drug Information File.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Hamilton Integrated Research Ethics Board (Hamilton, Ontario, Canada).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Individual patient consent was not required because only anonymized administrative data were interrogated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}